Use of anticoagulation at the time of discharge in patients with heart failure and atrial fibrillation

被引:7
作者
Pérez, IM
García, JM
Castroseiros, EF
Castelo, AG
Castro-Beiras, A
机构
[1] Complejo Hosp Univ Juan Canalejo, Serv Cardiol, Area Corzaon, La Coruna, Spain
[2] Univ A Coruna, Inst Ciencias Salud, La Coruna, Spain
[3] Complejo Hosp Cristal Pinor, Serv Cardiol, Orense, Spain
[4] Complejo Hosp Xeral Calde, Serv Cardiol, Lugo, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2003年 / 56卷 / 09期
关键词
anticoagulants; atrial fibrillation; heart failure;
D O I
10.1016/S0300-8932(03)76976-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives. To assess the degree of compliance with current guidelines for chronic anticoagulation in patients with heart failure and atrial fibrillation. Patients and method. From the INCARGAL Study database, we analyzed data from 195 consecutive patients (88 men; mean age 76 +/- 10 years) with both conditions, admitted to three Galician hospitals between January and March 1999. It was assumed that these patients should have received anticoagulant therapy at discharge, unless contraindicated. We studied the association of treatment at discharge (anticoagulation or not) with the presence or absence of contraindications. Results. 152 patients (78%) had no contraindication for anticoagulation and 43 had at least one (absolute: 11, relative: 32). Only 50% of patients without contraindications received anticoagulation at the time of discharge. No patient with an absolute contra indication and 3 with a relative one received anticoagulation. Factors related with the less frequent prescription of anticoagulation therapy in patients without a formal contraindication were: age, a previous history of coronary heart disease, absence of valvular heart disease, prior myocardial infarction, treatment with beta-blocking agents, non performance of an echocardiogram, and admission to a department other than cardiology. On multivariate analysis, age, prior myocardial infarction, and non-valvular disease were found to be independent predictors of less use of anticoagulation. Conclusions. Anticoagulant therapy is used less often than recommended at discharge in patients with heart failure and atrial fibrillation for whom there were no contraindications. Advanced age reduces its use. The presence of other indications for antiplatelet or anticoagulation therapy appears to determine the choice of one or the other. Noncompliance with the guidelines due to overprescription was not found.
引用
收藏
页码:880 / 887
页数:8
相关论文
共 37 条
[1]  
Almendral Garrote J, 2001, Rev Esp Cardiol, V54, P307
[2]   COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].
ALTMAN, R ;
CARRERAS, L ;
DIAZ, R ;
FIGUEROA, E ;
PAOLASSO, E ;
PARODI, JC ;
CADE, JF ;
DONNAN, G ;
EADIE, MJ ;
GAVAGHAN, TP ;
OSULLIVAN, EF ;
PARKIN, D ;
RENNY, JTG ;
SILAGY, C ;
VINAZZER, H ;
ZEKERT, F ;
ADRIAENSEN, H ;
BERTRANDHARDY, JM ;
BRAN, M ;
DAVID, JL ;
DRICOT, J ;
LAVENNEPARDONGE, E ;
LIMET, R ;
LOWENTHAL, A ;
MORIAU, M ;
SCHAPIRA, S ;
SMETS, P ;
SYMOENS, J ;
VERHAEGHE, R ;
VERSTRAETE, M ;
ATALLAH, A ;
BARNETT, H ;
BATISTA, R ;
BLAKELY, J ;
CAIRNS, JA ;
COTE, R ;
CROUCH, J ;
EVANS, G ;
FINDLAY, JM ;
GENT, M ;
LANGLOIS, Y ;
LECLERC, J ;
NORRIS, J ;
PINEO, GF ;
POWERS, PJ ;
ROBERTS, R ;
SCHWARTZ, L ;
SICURELLA, J ;
TAYLOR, W ;
THEROUX, P .
BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100
[3]   Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis [J].
Anand, SS ;
Yusuf, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2058-2067
[4]  
[Anonymous], 1994, Lancet, V343, P499
[5]  
Blackshear JL, 1996, LANCET, V348, P633
[6]  
BOISSEL JP, 1982, NEW ENGL J MED, V307, P701
[7]  
Brotons C, 1997, Aten Primaria, V20, P367
[8]   NONRHEUMATIC ATRIAL-FIBRILLATION - RISK OF STROKE AND ROLE OF ANTITHROMBOTIC THERAPY [J].
CAIRNS, JA ;
CONNOLLY, SJ .
CIRCULATION, 1991, 84 (02) :469-481
[9]  
Castelo AG, 2003, REV ESP CARDIOL, V56, P49
[10]  
Chesebro JH, 1996, ARCH INTERN MED, V156, P409